# Breakthrough Properties

> Breakthrough Properties is a Los Angeles-based life science real estate investor, developer, owner and operator created in 2019 by Tishman Speyer and Bellco Capital. It builds and runs specialized laboratories and R&D campuses for biotechnology, pharmaceutical and academic users, pairing real-estate execution with lab-operating knowledge, flexible StudioLabs suites and access to a scientific advisory network.

- **Founded:** 2019
- **Headquarters:** Los Angeles, United States
- **Founders:** Dan Belldegrun (CEO and Co-Founder)
- **Team size:** Approximately 110 employees in the supplied company dataset; LinkedIn lists 51-200 employees.
- **Products:** Life science development, Property ownership and operations, StudioLabs by Breakthrough, Investment management
- **Notable:** Raised $3 billion in direct capital and co-investments in 2022, double the original target., Built a portfolio described as nearly six million square feet across major US and European science clusters by 2025., Leased all 263,500 square feet of The 105 to CRISPR Therapeutics roughly one year after acquiring the Boston site.

## Products & services

- **Life science development** — Ground-up development and conversion of specialized laboratory, office and R&D buildings in established and emerging science clusters.
- **Property ownership and operations** — Long-term ownership, facilities operations, hospitality programming and property management for biotech, pharmaceutical and academic clients.
- **StudioLabs by Breakthrough** — Private turnkey wet-lab and office suites, generally 4,000 to 15,000 rentable square feet, with shorter leases, starter equipment, shared technical facilities and concierge support.
- **Investment management** — Institutional funds and co-investment vehicles pursuing development, repositioning and acquisition of life science properties in the US and Europe.

## Achievements

- Raised $3 billion in direct capital and co-investments in 2022, double the original target.
- Built a portfolio described as nearly six million square feet across major US and European science clusters by 2025.
- Leased all 263,500 square feet of The 105 to CRISPR Therapeutics roughly one year after acquiring the Boston site.
- Reached 100% leasing at the 520,000-square-foot Torrey View campus before construction completion, anchored by Pfizer and BD Biosciences.
- Launched StudioLabs in 2022; its first San Diego location was fully preleased to three venture-backed companies.
- Set a goal for whole-building operational net-zero carbon across the global portfolio by 2050 or sooner.

## Latest updates

- **2026-08** — Acquired a newly delivered 270,000-square-foot Seattle-area biomanufacturing facility for a reported $78 million through Growth Portfolio II.
- **2026-06** — Harvard, Tishman Speyer and Breakthrough celebrated completion of the first phase of the Enterprise Research Campus in Allston.
- **2026-01** — Protego Biopharma and AcelaBio leased a combined 20,682 square feet of furnished StudioLabs space at Governor Pointe in San Diego.
- **2025-11** — Growth Portfolio II held a reported $430 million first close and targeted $1.5 billion in total commitments.
- **2025-02** — Announced a partnership with the Stonewall Inn Gives Back Initiative.
- **2024-10** — Opened the fully leased, 520,000-square-foot Torrey View campus in San Diego.

## Links

- Website: https://www.btprop.com
- LinkedIn: https://www.linkedin.com/company/breakthroughproperties
- Twitter/X: https://twitter.com/bt_prop

---

Profile page: https://yespress.io/breakthrough-properties
Published by YesPress — https://yespress.io
Last updated: 2026-08-21